A customized approach to mRNA manufacturing
Webinar Date/Time: Wed, May 10, 2023 11:00 AM EDT
Participate in this webinar to gain insights into methods for furthering mRNA production programs and learn how to identify areas for development and streamline processes.
Register Free: https://www.biopharminternational.com/bp_w/customized-approach
Event Overview:
Diversity in mRNA therapies has mitigated advancements in the processes for manufacturing. IVT and capping reactions are not universal and must be finely tuned to each molecule based on composition, structure, and size. Using literature and experimental design, adapting each method to fit the molecule is necessary for hastening the optimization of mRNA development. In this webinar, you will gain insights into:
- Subject examination
- Identifying vital methodologies
- Refining and focusing target components
- Proper in-process analytics
Key Learning Objectives
- Identifying the variable/critical components involved in the mRNA production process
- Understanding the reasoning behind revisiting procedures
- Learning what metrics to use to navigate the mRNA process development
Who Should Attend
- Students/Researchers interested in developing better methods of in vitro transcribed RNA manufacturing
Speaker
Scott Alderucci
Director of mRNA Process Development & GMP operations
Curia Global, Inc.
Scott Alderucci is the director of process development overseeing the Process Development and GMP divisions of mRNA at Curia. He holds a scientific master’s degree and has 25 years of experience working in the field of biologics focused on DNA, mRNA and antibody platforms. He has worked within such institutions as Millennium Pharmaceuticals, Cellular Genomics, the State of Massachusetts, and Shire Pharmaceuticals prior to joining Curia. His current role is focused on providing research and development through GMP level production of a wide range of mRNA products to meet various program goals.
Register Free: https://www.biopharminternational.com/bp_w/customized-approach
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
